Evaluation of apoptotic effect of cyclic imide derivatives on murine B16F10 melanoma cells

被引:24
作者
Machado, Karina Elisa
de Oliveira, Kely Navakoski [2 ]
Santos-Bubniak, Lorena
Licinio, Marley Aparecida
Nunes, Ricardo Jose [2 ]
Santos-Silva, Maria Claudia [1 ]
机构
[1] Univ Fed Santa Catarina, Ctr Ciencias Saude, Dept Anal Clin, UFSC, BR-88040900 Florianopolis, SC, Brazil
[2] Univ Fed Santa Catarina, Dept Quim, UFSC, BR-88040900 Florianopolis, SC, Brazil
关键词
Cyclic imide derivatives; Cytotoxicity; Apoptotic effect; Murine B16F10 melanoma Cells; BIOLOGICAL EVALUATION; AMONAFIDE; CANCER; REPAIR; CYTOTOXICITY; METASTASIS; EXPRESSION; INHIBITORS; CARCINOMA; PATHWAYS;
D O I
10.1016/j.bmc.2011.09.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cyclic imides are a large class of compounds obtained by organic synthesis including several sub-classes (succinimides maleimide, glutarimide, phthalimides naphtalimides, and its derivatives). Recently, some cyclic imide derivatives have shown important results as potential antitumor agents, as a Mitonafide and Amonafide. Based on this fact, we have studied antitumoral properties of nine cyclic imide derivatives, four of which are unpublished compounds, against Murine Melanoma Cells (B16F10). Initially, the MTT assay was used to select the compound with the best cytotoxic potential. After this selection, the compound 2-benzyl-1H-benzo[de]isoquinoline-1,3(2H)-dione (4), which showed the best cytotoxic effects, was evaluated by flow cytometry, and a significant increase was observed in the proportion of cells in the subG0/G1, S and G2/M phases accompanied by a significant decrease in the G0/G1 phases. Then the mechanism involved on the death route (necrosis or apoptosis) was evaluated the by bromide and acridine orange method and by an Annexin V-FITC Apoptosis Detection kit. These results confirm that the percentage of B16F10 cells observed in the sub G0/G1 phase were undergoing apoptosis. The biological effects observed in the current study for the cyclic imide derivatives suggested promising applications, especially for the prototype compound 4. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6285 / 6291
页数:7
相关论文
共 45 条
[1]   Progression in cutaneous malignant melanoma is associated with distinct expression profiles -: A tissue microarray-based study [J].
Alonso, SR ;
Ortiz, P ;
Pollán, M ;
Pérez-Gómez, B ;
Sánchez, L ;
Acuña, MJ ;
Pajares, R ;
Martínez-Tello, FJ ;
Hortelano, CM ;
Piris, MA ;
Rodríguez-Peralto, JL .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :193-203
[2]  
Andricopulo AD, 1998, PHARMAZIE, V53, P493
[3]  
Andricopulo Adriano Defini, 1998, Acta Farmaceutica Bonaerense, V17, P219
[4]   Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs [J].
Antonini, Ippolito ;
Volpini, Rosaria ;
Dal Ben, Diego ;
Lambertucci, Catia ;
Cristalli, Gloria .
BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (18) :8440-8446
[5]   A GYNECOLOGIC-ONCOLOGY-GROUP PHASE-II STUDY OF AMONAFIDE (SC NUMBER-308847) IN SQUAMOUS-CELL CARCINOMA OF THE CERVIX [J].
ASBURY, RF ;
BLESSING, JA ;
SOPER, JT .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (02) :125-128
[6]  
CALIXTO JB, 1984, BRAZ J MED BIOL RES, V17, P313
[7]   Chemical aspects and therapeutic potential of cyclic imides:: A review [J].
Cechinel, V ;
de Campos, F ;
Corrêa, R ;
Yunes, RA ;
Nunes, RJ .
QUIMICA NOVA, 2003, 26 (02) :230-241
[8]  
CECHINEL V, 1994, FARMACO, V49, P675
[9]   A New Class of Naphthalimide-Based Antitumor Agents That Inhibit Topoisomerase II and Induce Lysosomal Membrane Permeabilization and Apoptosis [J].
Chen, Zhuo ;
Liang, Xin ;
Zhang, Huanying ;
Xie, Hua ;
Liu, Jianwen ;
Xu, Yufang ;
Zhu, Weiping ;
Wang, Yi ;
Wang, Xin ;
Tan, Shaoying ;
Kuang, Dong ;
Qian, Xuhong .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) :2589-2600
[10]   Cytotoxicity and lipid peroxidation-inhibiting activity of flavonoids [J].
Cos, P ;
Calomme, M ;
Sindambiwe, JB ;
De Bruyne, T ;
Cimanga, K ;
Pieters, L ;
Vlietinck, AJ ;
Vanden Berghe, D .
PLANTA MEDICA, 2001, 67 (06) :515-519